Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Календарь
Скринер
Новости
О нас

MRNA - Moderna, Inc. Последние новости | Finranks

Home

/

MRNA

M

Moderna, Inc. (MRNA)

NMS – Цена в реальном времени. Валюта: USD

64.17

+3.60 (5.94%)

Рынок открыт: Aug 12, 2026, 3:25 PM EDT

60.66

+0.09 (0.15%)

Предыдущая сессия: Aug 11, 2026, 7:57 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Moderna Q2 Earnings Call Highlights Cost Cuts and Pipeline Milestones

Moderna Q2 Earnings Call Highlights Cost Cuts and Pipeline Milestones

MRNA keeps its 2026 growth target intact while cutting cost guidance and advancing flu, oncology and rare-disease programs toward key milestones.

These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, Summit Therapeutics, and more.

This new kind of flu shot by Moderna has just been approved by the FDA

This new kind of flu shot by Moderna has just been approved by the FDA

The Food and Drug Administration has approved a new kind of flu vaccine for older people, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic, said the manufacturer, Moderna.The shot, named mFlusiva, is intended for adults who are 50 and older. Other brands of flu shots already have begun arriving in pharmacies ahead of fall vaccination season, and Moderna said late Wednesday that it expects some of its new version to be available soon at select retailers.While there already are multiple flu vaccine options in the U.S., including three specifically recommended for people age 65 or older, tens of thousands of Americans die from influenza every year and older adults are among the most vulnerable.Flu vaccines must be updated annually to best match circulating strains of the virus.

Moderna Stock Flashing Intriguing ‘Buy The Dip' Signal

Moderna Stock Flashing Intriguing ‘Buy The Dip' Signal

Moderna (MRNA) stock made a name for itself during the height of the pandemic, trading as high as $497 five years ago in 2021. Now, shares of the drugmaker sit at $55.12, pivoting lower despite the Food and Drug Administration (FDA) approving the company's flu vaccine.

Beyond COVID: Moderna Wins FDA Approval for Its Seasonal Flu Vaccine

Beyond COVID: Moderna Wins FDA Approval for Its Seasonal Flu Vaccine

The U.S. Food and Drug Administration (FDA) on Wednesday approved Moderna Inc.'s (NASDAQ:MRNA) mFLUSIVA (mRNA-1010), a new vaccine against seasonal influenza, for use in all adults 50 years and older.

Moderna Stock Climbs on Flu Vaccine Approval

Moderna Stock Climbs on Flu Vaccine Approval

Moderna Inc (NASDAQ:MRNA) is up 3.6% at $58.30 ahead of the open, after the U.S. Food and Drug Administration (FDA) approved the company's mRNA-based seasonal flu vaccine , mFluvis, for adults ages 50 and older.

Moderna Stock Rises as Flu Vaccine Approval Offers Spark for a Post-Pandemic Future

Moderna Stock Rises as Flu Vaccine Approval Offers Spark for a Post-Pandemic Future

Moderna's mRNA-based flu vaccine, mFlusiva, is approved by the Food and Drug Administration for adults aged 50 and over.

Видео

No Data

There is no data to display

Пресс-релизы

Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA

Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA

mFLUSIVA becomes Moderna's fifth approved product globally and fourth FDA-approved product Company expects supply to be available in select retailers in the coming weeks CAMBRIDGE, MA / ACCESS Newswire / August 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mFLUSIVA® (mRNA-1010), a new vaccine against seasonal influenza, for use in all adults 50 years and older. This approval follows unanimous recommendations from the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) supporting mFLUSIVA for adults 50 years of age and older.

Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna's Investigational Vaccine Against Bundibugyo Ebolavirus

Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna's Investigational Vaccine Against Bundibugyo Ebolavirus

Phase 1 trial will evaluate safety and immune response for a strain of Ebola virus disease with no licensed vaccines indicated Phase 1 trial is being conducted in Canada as part of our expanded collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI), building on Moderna's prior filovirus research CAMBRIDGE, MA / ACCESS Newswire / August 4, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that following Health Canada's authorization of the study, the first participants have been vaccinated in a Phase 1 clinical study in Canada evaluating mRNA-1469, the Company's investigational mRNA vaccine being evaluated to prevent Bundibugyo ebolavirus, or BDBV, disease. The vaccine candidate is being developed using Moderna's mRNA platform, the same technology that demonstrated rapid development, scalability, and global deployment capabilities during the COVID-19 pandemic.